Welcome!

News Feed Item

Envisia Therapeutics Announces Appointments to Board of Directors

Envisia Therapeutics today announced that it has made two appointments to the company’s board of directors. Effective immediately, Adrienne Graves, Ph.D. and Gary Phillips, M.D. will join the board as non-executive members.

“We are extremely honored to have these two respected industry leaders join the Board of Directors of Envisia early in the lifecycle of our company, which we believe is paving the way for a potentially transformative line of innovative ocular therapeutics,” said Neal Fowler, Chief Executive Officer of Envisia Therapeutics. “Both appointments bring invaluable perspective and insights that are greatly complementary to that of our existing board, forming a team that will collectively help us position Envisia as a leader in developing cutting-edge solutions for the ophthalmology community.”

A global thought leader in ophthalmology, Dr. Adrienne Graves currently serves as an independent director on a number of corporate boards, including Akorn, Inc.; TearLab Corporation; Aerpio Therapeutics; and Encore Vision. She is also a director on a number of ophthalmology-related foundation boards, including the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation (GRF), American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, and KeepYourSight Foundation. Dr. Graves also cofounded Glaucoma 360 (Glaucoma Research Foundation) and Ophthalmic Women Leaders (OWL). Additionally, she serves on the Corporation Committee for the Brown University Medical School and the Advisory Board for Amach Capital Partners.

“Much progress has been made in the field of ophthalmology; however, the rate of preventable vision loss and blindness continues to rise and underscores the near-term need for truly innovative ocular therapies,” said Adrienne Graves, Ph.D. “Envisia’s application of the PRINT® technology to address unmet needs in ophthalmology could have a profound impact on our ability to reduce the rate of preventable vision loss, and I look forward to working with the company on its efforts to achieve this worthy goal.”

Dr. Graves was formerly President and Chief Executive Officer of Santen USA, a division of Santen Co. Ltd., Japan’s largest ophthalmic pharmaceutical company. She started her successful career with Santen USA in 1995 as Vice President of Clinical Affairs with responsibility for initiating the company’s U.S. clinical program, which included the approval of three New Drug Applications. Prior to joining Santen, she spent nine years with Alcon Laboratories, Inc., beginning as a Senior Scientist and then advancing into various roles, including Director of International Ophthalmology. Dr. Graves received her AB in Psychology with honors from Brown University and her Ph.D. in Psychobiology from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris.

Dr. Gary Phillips has more than 20 years’ experience in strategy, business development and licensing, commercial operations, business analytics, and clinical medicine in the pharmaceutical and healthcare industries. He is currently the Senior Vice President and Chief Strategy Officer at Mallinckrodt Pharmaceuticals.

“The ophthalmology market is attractive and highly concentrated among a few competitors; therefore, new entrants must be clearly differentiated through improved technologies that deliver marked improvement in patient outcomes while reducing the cost burden on patients and the healthcare system,” said Gary Phillips, M.D. “Through its unique combination of talent, technology, and vision, Envisia is well positioned to compete in this market, and I look forward to working with the company’s board and management team toward the goal of maximizing its potential in the years to come.”

Before joining Mallinckrodt, Dr. Phillips served as Head of Global Health and Healthcare Industries at the World Economic Forum in Geneva, Switzerland. Previously, he was President of Reckitt Benckiser Pharmaceuticals, Inc., and held the dual roles of President, U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals at Bausch & Lomb Incorporated. He has also held executive roles at Merck Serono, Novartis, and Wyeth (now Pfizer) and served as a healthcare strategy management consultant at Towers Perrin (now Towers Watson) and as a medical officer with the United States Navy. Dr. Phillips attended the University of Pennsylvania, where he earned a medical degree from the School of Medicine, an MBA from the Wharton School, and a Bachelor’s degree summa cum laude in biochemistry from the College of Arts and Sciences. He completed his postgraduate medical education at Naval Medical Center San Diego.

ABOUT ENVISIA THERAPEUTICS™

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately-held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, implantable extended-release formulation of travoprost (a marketed prostaglandin analogue) that has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina. For more information, please visit www.envisiatherapeutics.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
SYS-CON Events announced today that Daiya Industry will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Daiya Industry specializes in orthotic support systems and assistive devices with pneumatic artificial muscles in order to contribute to an extended healthy life expectancy. For more information, please visit https://www.daiyak...
SYS-CON Events announced today that Nihon Micron will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Nihon Micron Co., Ltd. strives for technological innovation to establish high-density, high-precision processing technology for providing printed circuit board and metal mount RFID tags used for communication devices. For more inf...
SYS-CON Events announced today that Massive Networks, that helps your business operate seamlessly with fast, reliable, and secure internet and network solutions, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. As a premier telecommunications provider, Massive Networks is headquartered out of Louisville, Colorado. With years of experience under their belt, their team of...
SYS-CON Events announced today that Suzuki Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Suzuki Inc. is a semiconductor-related business, including sales of consuming parts, parts repair, and maintenance for semiconductor manufacturing machines, etc. It is also a health care business providing experimental research for...
"Our strategy is to focus on the hyperscale providers - AWS, Azure, and Google. Over the last year we saw that a lot of developers need to learn how to do their job in the cloud and we see this DevOps movement that we are catering to with our content," stated Alessandro Fasan, Head of Global Sales at Cloud Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
Many organizations adopt DevOps to reduce cycle times and deliver software faster; some take on DevOps to drive higher quality and better end-user experience; others look to DevOps for a clearer line-of-sight to customers to drive better business impacts. In truth, these three foundations go together. In this power panel at @DevOpsSummit 21st Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, industry experts will discuss how leading organizations build application success from all...
SYS-CON Events announced today that mruby Forum will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. mruby is the lightweight implementation of the Ruby language. We introduce mruby and the mruby IoT framework that enhances development productivity. For more information, visit http://forum.mruby.org/.
Cloud-based disaster recovery is critical to any production environment and is a high priority for many enterprise organizations today. Nearly 40% of organizations have had to execute their BCDR plan due to a service disruption in the past two years. Zerto on IBM Cloud offer VMware and Microsoft customers simple, automated recovery of on-premise VMware and Microsoft workloads to IBM Cloud data centers.
Why Federal cloud? What is in Federal Clouds and integrations? This session will identify the process and the FedRAMP initiative. But is it sufficient? What is the remedy for keeping abreast of cutting-edge technology? In his session at 21st Cloud Expo, Rasananda Behera will examine the proposed solutions: Private or public or hybrid cloud Responsible governing bodies How can we accomplish?
Today traditional IT approaches leverage well-architected compute/networking domains to control what applications can access what data, and how. DevOps includes rapid application development/deployment leveraging concepts like containerization, third-party sourced applications and databases. Such applications need access to production data for its test and iteration cycles. Data Security? That sounds like a roadblock to DevOps vs. protecting the crown jewels to those in IT.
SYS-CON Events announced today that Cedexis will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Cedexis is the leader in data-driven enterprise global traffic management. Whether optimizing traffic through datacenters, clouds, CDNs, or any combination, Cedexis solutions drive quality and cost-effectiveness.
Elon Musk is among the notable industry figures who worries about the power of AI to destroy rather than help society. Mark Zuckerberg, on the other hand, embraces all that is going on. AI is most powerful when deployed across the vast networks being built for Internets of Things in the manufacturing, transportation and logistics, retail, healthcare, government and other sectors. Is AI transforming IoT for the good or the bad? Do we need to worry about its potential destructive power? Or will we...